CVRx, Inc.
Financials
Valuation Metrics
CVRx, Inc.'s Market Cap is $37M. At end of 2025 it was $186M. Ranked #3087 of 3,114 in US market (top 99%), #1447 of 1,469 on NASDAQ (top 99%), #199 of 203 in Health Care Equipment & Services (top 98%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $37M | US#3,087/3,114 Sec#199/203 |
| Revenue | $61M | US#2,730/3,114 Sec#193/203 |
| Net Income | $-52M | US—/3,114 Sec—/203 |
| Total Assets | $92M | US#3,058/3,114 Sec#201/203 |
| Net Assets | $20M | US#2,888/3,114 Sec#189/203 |
| Employees | 223 | US#2,468/3,114 Sec#170/203 |
| Value | ||
| P/B | 1.88x | US#1,148/3,114 Sec#48/203 |
| P/S | 0.61x | US#401/3,114 Sec#32/203 |
| FCF Yield | -109.72% | US—/3,114 Sec—/203 |
| Profitability | ||
| ROA | -56.31% | US#3,008/3,114 Sec#199/203 |
| Op. Margin | -79.49% | US#2,693/3,114 Sec#191/203 |
| Revenue Growth | 11.96% | US#1,089/3,114 Sec#74/203 |
| Financial Health | ||
| Debt Ratio | 362.50% | US#2,225/3,114 Sec#173/203 |
| Total Debt | $59M | US#2,577/3,114 Sec#153/203 |
| FCF | $-41M | US#2,506/3,114 Sec#174/203 |
| Cash | $65M | US#2,460/3,114 Sec#152/203 |
| Current Ratio | 8.04x | US#314/3,114 Sec#21/203 |
| Performance | ||
| 1Y Return | -86.75% | US#3,099/3,114 Sec#199/203 |
| 1M Return | -19.43% | US#3,088/3,114 Sec#202/203 |
| From 52W High | -87.52% | US#3,092/3,114 Sec#201/203 |
| 1Y MDD | -87.97% | US#3,089/3,114 Sec#201/203 |
| Trading | ||
| Volume | 237,698 shares | US#2,549/3,114 Sec#172/203 |
| Trading Value | $337531.00 | US#3,078/3,114 Sec#196/203 |
| Per Share | ||
| EPS | $-1.96 | US—/3,114 Sec—/203 |
| BPS | $0.75 | US#2,720/3,114 Sec#183/203 |
Company Info
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.